A Case Series of 36 Patients Treated for Old World Cutaneous leishmaniasis.

Zahra Saffarian, Zahra Vasfi Marandi, Safoura Shakoei, Shahin Hamzelou, Sima Rafati

Abstract readCase Reports

In one paragraph

Article in The Journal of clinical and aesthetic dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zahra SaffarianDrs. Saffarian and Shakoei are with the Dermatology Department of Imam Khomeini Hospital Complex and Razi Dermatology Hospital at Tehran University of Medical Science in Tehran, Iran.

Zahra Vasfi MarandiDr. Marandi is with the Dermatology Department of Imam Khomeini Hospital Complex School of Medicine at Tehran University of Medical Science in Tehran, Iran.

Safoura ShakoeiDrs. Saffarian and Shakoei are with the Dermatology Department of Imam Khomeini Hospital Complex and Razi Dermatology Hospital at Tehran University of Medical Science in Tehran, Iran.

Shahin HamzelouDr. Hamzelou is with the Dermatology Department of Imam Khomeini Hospital Complex and Razi Dermatology Hospital at Tehran University of Medical Science in Tehran, Iran.

Sima RafatiDr. Rafati is with the Department of Immunotherapy and Leishmania Vaccine Research at the Pasteur Institute of Iran in Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cutaneous leishmaniasis is endemic in Iran. Objective: We sought to investigate the therapeutic outcomes and complications of treatment in patients with cutaneous leishmaniasis. Methods: This case series enrolled patients with smear-proven cutaneous leishmaniasis who visited our center in Iran from 2018 to 2019. Results: In total, 36 patients were treated with intralesional meglumine antimoniate, intramuscular meglumine antimoniate, sodium stibogluconate, and amphotericin B. Overall, this treatment was effective in 81.8 percent of patients. Relapse and treatment failure occurred in 6.1 percent and 12.1 percent of patients, respectively. Treatment with intralesional meglumine antimoniate, intramuscular meglumine antimoniate, sodium stibogluconate, and amphotericin B yielded a clearance rate of 80.8 percent, 92.3 percent, 75 percent, and 85.7 percent, respectively. Clearance was associated with a shorter time interval between injections of intralesional meglumine antimoniate ( Limitations: Low sample size was the limitation of this study. Conclusion: The cure rate of intramuscular meglumine antimoniate was higher than amphotericin B, which was higher than the cure rate of sodium stibogluconate. In patients treated with intralesional meglumine antimoniate, reducing the time interval between injections increased the clearance rate and decreased the rate of relapse.

Indexed as

adverse effectsamphotericin BCutaneous leishmaniasispentavalent antimonialstreatment outcome

Identifiers

PMID39006810

PMCPMC11238713

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.